JP2022504400A5 - - Google Patents
Info
- Publication number
- JP2022504400A5 JP2022504400A5 JP2021518905A JP2021518905A JP2022504400A5 JP 2022504400 A5 JP2022504400 A5 JP 2022504400A5 JP 2021518905 A JP2021518905 A JP 2021518905A JP 2021518905 A JP2021518905 A JP 2021518905A JP 2022504400 A5 JP2022504400 A5 JP 2022504400A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variant
- amino acid
- variant according
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024133817A JP7818850B2 (ja) | 2018-10-08 | 2024-08-09 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742682P | 2018-10-08 | 2018-10-08 | |
| US62/742,682 | 2018-10-08 | ||
| US201862775563P | 2018-12-05 | 2018-12-05 | |
| US62/775,563 | 2018-12-05 | ||
| US201862779104P | 2018-12-13 | 2018-12-13 | |
| US62/779,104 | 2018-12-13 | ||
| US201962808601P | 2019-02-21 | 2019-02-21 | |
| US62/808,601 | 2019-02-21 | ||
| US201962846904P | 2019-05-13 | 2019-05-13 | |
| US62/846,904 | 2019-05-13 | ||
| PCT/US2019/055178 WO2020076817A1 (en) | 2018-10-08 | 2019-10-08 | Engineering of dnase enzymes for manufacturing and therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133817A Division JP7818850B2 (ja) | 2018-10-08 | 2024-08-09 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022504400A JP2022504400A (ja) | 2022-01-13 |
| JP2022504400A5 true JP2022504400A5 (https=) | 2022-10-14 |
Family
ID=70164727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518905A Pending JP2022504400A (ja) | 2018-10-08 | 2019-10-08 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
| JP2024133817A Active JP7818850B2 (ja) | 2018-10-08 | 2024-08-09 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133817A Active JP7818850B2 (ja) | 2018-10-08 | 2024-08-09 | 製造及び治療のためのｄｎａｓｅ酵素の操作 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11578314B2 (https=) |
| EP (1) | EP3864147A4 (https=) |
| JP (2) | JP2022504400A (https=) |
| KR (1) | KR20210072790A (https=) |
| CN (1) | CN112996911A (https=) |
| AU (2) | AU2019358915B2 (https=) |
| BR (1) | BR112021006737A2 (https=) |
| CA (1) | CA3115766A1 (https=) |
| IL (2) | IL325846A (https=) |
| MX (1) | MX2021004022A (https=) |
| SG (1) | SG11202103426XA (https=) |
| WO (1) | WO2020076817A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019209770B2 (en) | 2018-01-16 | 2025-07-31 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| EP4161645A4 (en) * | 2020-06-08 | 2023-11-01 | Yale University | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING COAGULOPATHY AND/OR SEPSIS IN PATIENTS WITH BACTERIAL AND/OR VIRAL INFECTIONS |
| EP4294824A4 (en) * | 2021-02-17 | 2025-01-01 | Neutrolis Inc. | DNASE 1-LIKE 2 MANIPULATED FOR PRODUCTION AND USE IN THERAPY |
| CA3219838A1 (en) * | 2021-05-21 | 2022-11-24 | Dmitry Dmitrievich Genkin | Immunomodulation of tumor microenvironment |
| EP4448743A4 (en) * | 2021-12-15 | 2026-01-14 | Univ Texas Tech System | IMPROVEMENT IN THE SERUM HALF-LIFE OF DNASE1L3 |
| WO2025076525A1 (en) * | 2023-10-06 | 2025-04-10 | Neutrolis, Inc. | Biomarker and precision therapy for inflammatory disease |
| WO2026037276A1 (zh) * | 2024-08-12 | 2026-02-19 | 上海交通大学医学院 | 一种减少线粒体dna泄露的方法 |
| CN120424194A (zh) * | 2025-04-30 | 2025-08-05 | 苏州泓迅生物科技股份有限公司 | 一种重组人源纤连蛋白的制备方法及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6656685B2 (en) * | 2001-01-29 | 2003-12-02 | Ventana Medical Systems, Inc. | Hybridization buffers using low molecular weight dextran sulfate and methods for their use |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US20040138156A1 (en) * | 2002-02-26 | 2004-07-15 | Schneider Michael C | Therapeutic regulation of deoxyribonuclease-1-like-3 activity |
| EP1440981A3 (en) * | 2003-01-21 | 2005-11-23 | Research Association for Biotechnology | Full-length human cdna |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| US9248166B2 (en) | 2003-07-14 | 2016-02-02 | Cls Therapeutics Limited | Method for treating oncological diseases |
| WO2006130034A1 (fr) | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| RU2269356C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| EP2416156B1 (en) | 2006-10-18 | 2015-12-30 | Periness Ltd. | Method for determining a male fertility status |
| US20090305345A1 (en) | 2006-10-23 | 2009-12-10 | Medical Research Council | Polymerase |
| AU2008279550B2 (en) | 2007-06-21 | 2012-08-09 | Angelica Therapeutics, Inc. | Modified toxins |
| MX341084B (es) * | 2009-11-02 | 2016-08-05 | Univ Washington | Composiciones de nucleasas terapéuticas y métodos. |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| EP2561367A1 (en) | 2010-04-22 | 2013-02-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| CN107188970A (zh) | 2010-06-04 | 2017-09-22 | 株式会社蒂奥姆生物 | 具有因子vii活性的融合蛋白质 |
| WO2012106264A2 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of Columbia University In The City Of New York | Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections |
| AU2012222833B2 (en) * | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| ES2666303T3 (es) * | 2011-04-29 | 2018-05-03 | University Of Washington | Composiciones terapéuticas de nucleasa y métodos |
| WO2012166611A2 (en) | 2011-05-27 | 2012-12-06 | Immune Disease Institute, Inc. | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| ES2666856T3 (es) * | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
| US9867871B2 (en) | 2011-12-12 | 2018-01-16 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| GB201208879D0 (en) | 2012-05-21 | 2012-07-04 | London School Hygiene & Tropical Medicine | Therapeutic for treating Clostridium difficile infection |
| WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| CN107249621A (zh) | 2014-09-08 | 2017-10-13 | 哥谭生物制药股份有限公司 | 用于治疗肺结节病的粘液溶解剂 |
| EP3265814B1 (en) | 2015-03-01 | 2020-11-18 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
| EP3273238A1 (en) | 2016-07-22 | 2018-01-24 | Universitätsklinikum Hamburg-Eppendorf | Immunodiagnostic detection of anti-neutrophil antibodies |
| CA3036926C (en) | 2016-09-30 | 2022-05-31 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| EP3570667B1 (en) * | 2017-01-20 | 2022-11-16 | Neutrolis Inc. | Animal model for drug development |
| DK3668972T3 (da) * | 2017-08-18 | 2025-01-13 | Neutrolis Inc | Konstruerede dnase-enzymer og anvendelse i terapi |
| US10988746B2 (en) * | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| WO2020163264A1 (en) * | 2019-02-04 | 2020-08-13 | Neutrolis, Inc. | Engineered human extracellular dnase enzymes for drug candidate selection |
| EA202190940A1 (ru) * | 2019-05-13 | 2021-10-15 | Ньютролис Инк. | РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ |
| EP4294824A4 (en) * | 2021-02-17 | 2025-01-01 | Neutrolis Inc. | DNASE 1-LIKE 2 MANIPULATED FOR PRODUCTION AND USE IN THERAPY |
-
2019
- 2019-10-08 IL IL325846A patent/IL325846A/en unknown
- 2019-10-08 CA CA3115766A patent/CA3115766A1/en active Pending
- 2019-10-08 JP JP2021518905A patent/JP2022504400A/ja active Pending
- 2019-10-08 IL IL282058A patent/IL282058B1/en unknown
- 2019-10-08 KR KR1020217013090A patent/KR20210072790A/ko active Pending
- 2019-10-08 MX MX2021004022A patent/MX2021004022A/es unknown
- 2019-10-08 EP EP19870853.9A patent/EP3864147A4/en active Pending
- 2019-10-08 BR BR112021006737-0A patent/BR112021006737A2/pt unknown
- 2019-10-08 SG SG11202103426XA patent/SG11202103426XA/en unknown
- 2019-10-08 CN CN201980073970.5A patent/CN112996911A/zh active Pending
- 2019-10-08 WO PCT/US2019/055178 patent/WO2020076817A1/en not_active Ceased
- 2019-10-08 AU AU2019358915A patent/AU2019358915B2/en active Active
-
2022
- 2022-02-10 US US17/668,674 patent/US11578314B2/en active Active
-
2023
- 2023-10-30 US US18/497,106 patent/US12565642B2/en active Active
-
2024
- 2024-08-09 JP JP2024133817A patent/JP7818850B2/ja active Active
-
2025
- 2025-12-17 AU AU2025283522A patent/AU2025283522B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022504400A5 (https=) | ||
| Shao et al. | Advancements of Annexin A1 in inflammation and tumorigenesis | |
| Calvo et al. | Function and evolution of a mosquito salivary protein family | |
| Price et al. | The biochemistry of cancer dissemination | |
| US20080227691A1 (en) | Blood Coagulation FVIII Analogues | |
| JP2012235793A (ja) | プロテアーゼ阻害 | |
| EP2215264B1 (en) | Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8 | |
| JP2012512645A5 (https=) | ||
| Meens et al. | Risky communication in atherosclerosis and thrombus formation | |
| JP2011518179A5 (https=) | ||
| JP2017521074A5 (https=) | ||
| JP2025016467A (ja) | 改善された薬物動態を有する、グリコシル化ｖｗｆ融合タンパク質 | |
| JP2022504400A (ja) | 製造及び治療のためのｄｎａｓｅ酵素の操作 | |
| JP2011184453A (ja) | プラスミン阻害療法 | |
| TWI670075B (zh) | 一種預防和治療肝纖維化的方法 | |
| JP7194440B2 (ja) | 心臓病変を改善するための方法 | |
| WO2023072311A1 (zh) | 宽体金线蛭抗凝血因子XIa多肽及其应用 | |
| JP5751519B2 (ja) | 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質 | |
| JP2021046437A (ja) | サイトカインストーム抑制剤 | |
| KR20190039944A (ko) | 지속성 응고 인자 vii 및 그 제조 방법 | |
| US6906037B2 (en) | Therapeutic peptide-based constructs | |
| TWI638830B (zh) | 附加唾液酸化糖鏈之多肽 | |
| CN108404119B (zh) | Fgf-21类似物的制备及在血栓治疗中的应用 | |
| US20120077733A1 (en) | Antagonists against interaction of pf4 and rantes | |
| JP2009528831A (ja) | キメラＫｕｎｉｔｚドメインおよびその使用 |